Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$280.13
▼ $4.63 (-1.6%)
Market data updated: 09/18 02:25 AM
Fundamentals updated: 09/17/2026
News analyzed: 09/18/2026
Market Cap
$107.45B
Day Range
$279.09 - $286.13
52-Week Range
$267.00 - $392.55
Beta
—
Next Earnings
28.10.2026
SYK is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-24.4% (1Y)
Strengths: 8/32 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Free cash flow growth
Free cash flow growth: 22.8%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: $179.86 vs. price $280.13 (-35.8%)
Fair Value
Signal tension
Growth scores strong (67/100), but fair-value analysis scores this stock as relatively expensive (38/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
50
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
67
Quality
58
Value
38
Momentum
20
Risk
48
Sentiment
68
Fundamental
71
Institutional
0
Stocks with a similar DNA right now
SCANNING SYK...
Recent media coverage of Stryker Corporation has focused on its strategic expansion and market positioning. Notably, the company announced plans to acquire ZuriMED, adding the FiberLocker System to its shoulder portfolio, signaling growth in orthopedic solutions. Additionally, Stryker’s stock faced a decline due to broader industry supply chain challenges. The company also participated in the 2026 Wells Fargo Healthcare Conference, highlighting investor engagement amid evolving market trends. No direct mention of cybersecurity incidents or major financial guidance shifts was tied to Stryker itself.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Stryker Corporation. News trend score: 68. Reason: 7 of the last 20 articles are positive, versus 4 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
29
🎯 Conviction (vs. Emotion)
41
Psychology
45
Fundamentals
71
Technical
20
Valuation
38
The price rise has far outpaced the actual improvement in fundamental data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
-7%
Market Narrative
52
Fundamental Reality
41
Narrative Gap
+11
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market’s dominant **anchoring** behavior reflects traders’ fixation on the 0.5% support level, despite contradictory signals like extreme sentiment (100/100) and oversold conditions (RSI 21). The **narrative gap** (65 vs. 41) suggests investors may overestimate positive fundamentals relative to technical reality. **Overconfidence** (45) and **euphoria** (33) hint at mispricing, while **herding** (32) implies peer performance drives alignment. The key question: Will traders break free from the support anchor, or will the gap between narrative and reality widen further?
Updated: 09/09/2026, 09:17 AM
What could change this?
👥 What the crowd believes
"Stryker signed a definitive agreement to acquire privately held ZuriMED, which would add the commercialized FiberLocker System to its shoulder portfolio"
"Both Intuitive Surgical and Stryker just posted their fifth straight earnings beat, and Wall Street is cheering for both"
"Global Surgical Robots Market to Reach $10.6 Billion in 2026, Driven by AI Integration and Minimally Invasive Surgery"
"Supply chain woes send Stryker stock tumbling 7.7%"
📈 12D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 90/100
🔴 Weakest match
Benjamin Graham — 17/100
🗣️ Why do they disagree?
The stark divide in verdicts for SYK reflects deep methodological differences in how these investors assess stocks. Samuel Armstrong Nelson’s near-perfect score and bullish cycle call contrast sharply with Jesse Livermore’s outright rejection, as Livermore’s trend-following discipline clashes with Nelson’s contrarian oversold bias. Meanwhile, Fisher, Smith, and Marks (cycle) lean cautiously positive, valuing growth potential or market positioning, while Graham’s rigid defensive criteria and Lynch’s strict valuation bar dismiss it outright. The middle ground—where Bagehot, Veblen, and Housel see moderate merit but not exceptional quality—highlights a stock that may appeal to some frameworks (like Smith’s long-term hold thesis) but fails to meet the strictest standards (e.g., Livermore’s trend alignment or Graham’s margin of safety).
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 90
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 77
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 77
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 71
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 71
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 61
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟡 57
Adequate but not exceptional liquidity
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 52
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 51
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 49
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 46
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 45
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 31
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 20
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 17
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Based on the last 278 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 9 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
64.0%
Operating Margin
19.5%
Net Margin
12.9%
EBITDA Margin
25.7%
ROE
14.5%
ROA
6.8%
ROIC
—
EPS
$8.49
Cash
$4.01B
Total Debt
$15.86B
Current Ratio
1.89
Debt/Equity
0.71
Total dividend per share paid each year, over the last 5 years.
| Ex-Dividend Date | Amount per Share |
|---|---|
| 30.6.2026 | $0.880 |
| 29.6.2026 | $0.880 |
| 31.3.2026 | $0.880 |
| 30.3.2026 | $0.880 |
| 31.12.2025 | $0.880 |
| 30.12.2025 | $0.880 |
| 30.9.2025 | $0.840 |
| 29.9.2025 | $0.840 |
| 30.6.2025 | $0.840 |
| 29.6.2025 | $0.840 |
| 31.3.2025 | $0.840 |
| 30.3.2025 | $0.840 |
How is Fair Value calculated? →
Current Price
$280.13
Estimated Fair Value (DCF)
$179.86
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-35.8%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
10.8%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 10.8% | $4.75B | $4.35B |
| 2 | 8.7% | $5.16B | $4.34B |
| 3 | 6.7% | $5.51B | $4.25B |
| 4 | 4.6% | $5.76B | $4.08B |
| 5 | 2.5% | $5.90B | $3.84B |
Base FCF (last actual year)
$4.28B
Terminal Value
$93.08B
Present Value of Terminal Value
$60.50B
Enterprise Value
$81.36B
Net Debt
$11.85B
Equity Value
$69.51B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$58.01
Tangible Book Value per Share (Tangible NAV)
-$6.60
Sentiment based on basic keywords (not AI) — 7 positive, 9 neutral, 4 negative out of the last 20 articles.
Yahoo · 17.9.2026
Yahoo · 17.9.2026
Yahoo · 17.9.2026
Yahoo · 17.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
ChartMill · 16.9.2026
SeekingAlpha · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 15.9.2026
Yahoo · 15.9.2026
Trefis · 14.9.2026
Yahoo · 14.9.2026
Zacks · 14.9.2026
Yahoo · 14.9.2026
Trefis · 14.9.2026
Yahoo · 14.9.2026
MT Newswires · 14.9.2026
SeekingAlpha · 14.9.2026
Trefis · 11.9.2026
Stryker Corporation (SYK) currently has a StockIQ AI score of 50/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
SYK currently scores 50/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, SYK's estimated fair value is $179.86, which is 35.8% below the current price of $280.13. This is one valuation model among several signals in the fair-value category, not a price target.
SYK's technical score is 20/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Free cash flow growth: 22.8%; Operating margin is stable or improving over time; Current ratio: 1.89.
Based on the real signals StockIQ computed: Estimated fair value: $179.86 vs. price $280.13 (-35.8%); Calmar: -0.03 (3y annualized return -1.0% / max drawdown 33.1%); Price is below the 50-day average.
Yes — SYK has a real recorded dividend payment history on StockIQ. See the Dividends section on this page for the actual per-share amounts and dates.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 23 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Crotty Dylan Bram | Open Market Sale | 21.8.2026 | 6,102 | -441 | $328.61 |
| Crotty Dylan Bram | Open Market Sale | 21.8.2026 | 441 | -441 | $328.61 |
| STRYKER RONDA E | Open Market Sale | 19.8.2026 | 805 | -805 | $343.47 |
| STRYKER RONDA E | Open Market Sale | 19.8.2026 | 3,852 | -3,852 | $342.80 |
| STRYKER RONDA E | Open Market Sale | 19.8.2026 | 3,274 | -3,274 | $341.84 |
| STRYKER RONDA E | Open Market Sale | 19.8.2026 | 16,612 | -16,612 | $340.71 |
| STRYKER RONDA E | Open Market Sale | 19.8.2026 | 10,812 | -10,812 | $339.71 |
| STRYKER RONDA E | Open Market Sale | 19.8.2026 | 11,257 | -11,257 | $338.90 |
| STRYKER RONDA E | Open Market Sale | 19.8.2026 | 2,308 | -2,308 | $337.98 |
| STRYKER RONDA E | Open Market Sale | 19.8.2026 | 80 | -80 | $335.06 |
| STRYKER RONDA E | Open Market Sale | 19.8.2026 | 320 | -320 | $336.79 |
| STRYKER RONDA E | Open Market Sale | 19.8.2026 | 200 | -200 | $333.93 |
| STRYKER RONDA E | Open Market Sale | 19.8.2026 | 440 | -440 | $333.18 |
| STRYKER RONDA E | Open Market Sale | 19.8.2026 | 40 | -40 | $331.81 |
| King Debra | Open Market Sale | 18.8.2026 | 826 | -826 | $336.30 |
| STRYKER RONDA E | Open Market Sale | 18.8.2026 | 3,481 | -3,481 | $338.50 |
| STRYKER RONDA E | Open Market Sale | 18.8.2026 | 16,243 | -16,243 | $337.63 |
| STRYKER RONDA E | Open Market Sale | 18.8.2026 | 131,752 | -131,752 | $335.64 |
| STRYKER RONDA E | Open Market Sale | 18.8.2026 | 109,425 | -109,425 | $336.43 |
| STRYKER RONDA E | Open Market Sale | 18.8.2026 | 25,536 | -25,536 | $334.95 |
| STRYKER RONDA E | Open Market Sale | 18.8.2026 | 8,404 | -8,404 | $333.83 |
| STRYKER RONDA E | Open Market Sale | 18.8.2026 | 2,920 | -2,920 | $332.69 |
| STRYKER RONDA E | Open Market Sale | 18.8.2026 | 2,239 | -2,239 | $331.74 |
| Fink M Kathryn | Tax Withholding in Shares | 1.8.2026 | 111 | -111 | $325.70 |
| Fletcher Robert S | Tax Withholding in Shares | 1.8.2026 | 94 | -94 | $325.70 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
7,643,592 shares short as of 2026-08-31 · vs. 8,329,304 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
47.3% of trading volume this week was short selling, vs. 41.4% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology